FGF23 and chronic kidney disease: The benefit of aspirin therapy in the primary prevention of CVD among CKD needs to be further explored, because multiple risk factors contribute to CVD in CKD patients, including increased oxidative stress, endothelial dysfunction, vascular calcifications, and increased fibroblast growth factor 23.